AstraZeneca is calling off two late-stage trials into the potential benefits of its potassium-reduction drug Lokelma in treating a chronic condition called hyperkalemia in people with various heart and kidney diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,